Research

Family Friendly Research Poster Session Presenters Announced

June 11, 2019
Posted in , ,

The Family Friendly Research Poster Session will be held on Saturday, June 29th from 6:30pm to 8:00pm at the 2019 Annual SMA Conference.  The Family […]

Read More ›

Biogen Issues Q2 Community Statement on Spinraza

June 6, 2019
Posted in , ,

Dear members of the SMA community, We are grateful for the opportunity to continue to help support individuals with spinal muscular atrophy (SMA), their caregivers […]

Read More ›

Scholar Rock Announces Positive Final Results from Phase 1 Clinical Trial of SRK-015 in Healthy Volunteers

June 4, 2019
Posted in , ,

Scholar Rock today announced positive final top-line results from the Phase 1 clinical trial of its product candidate, SRK-015, a highly specific inhibitor of myostatin […]

Read More ›

AveXis and Cure SMA to Co-Host Webinar on the FDA’s Approval of Zolgensma

May 24, 2019
Posted in ,

On Wednesday, June 12th, at 10am CDT (8am PDT/9am MDT/11am EDT) AveXis, a Novartis company, and Cure SMA will co-host a webinar on the FDA […]

Read More ›

AveXis Issues Community Statement on Zolgensma Approval

May 24, 2019
Posted in , ,

Dear SMA Community, We have exciting news to share with you — a major milestone has been reached in the fight against spinal muscular atrophy […]

Read More ›

AveXis Receives FDA Approval of Zolgensma, a Gene Therapy, for Spinal Muscular Atrophy for Patients Under Two Years of Age

May 24, 2019
Posted in , ,

AveXis, Inc., a Novartis company, today announced that they have received FDA approval for Zolgensma (formerly AVXS-101), a gene therapy that replaces the survival motor […]

Read More ›

Cure SMA Awards $150,000 Grant to Krysta Engel, PhD, University of Colorado

May 21, 2019
Posted in , ,

Audrey Lewis founded Families of SMA, now Cure SMA, 34 years ago. Audrey recognized early on the importance of attracting new and talented researchers to […]

Read More ›

Novartis Issues Community Statement on Branaplam Clinical Study

May 16, 2019
Posted in , ,

Dear SMA Community, We are writing to inform you that enrollment to the ongoing branaplam clinical study is now closed. Branaplam is currently being assessed […]

Read More ›

Cure SMA Publishes Journal Article on Benefit-Risk Preferences in SMA

May 14, 2019
Posted in , ,

Your voice has been heard! Cure SMA has published a paper, titled, Evaluating Benefit-Risk Decision-Making in Spinal Muscular Atrophy: A First-Ever Study to Assess Risk Tolerance […]

Read More ›

Dr. Arthur Burghes Named 2019 Distinguished Scholar

May 8, 2019
Posted in ,

The Ohio State University recently announced the 2019 honorees of the Distinguished Scholar Award. The award, established in 1978, recognizes exceptional scholarly accomplishments by senior […]

Read More ›
Scroll to Top